Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update
Date:8/7/2008

Studies to be presented will include:

* A Phase 2, 185-patient randomized, placebo-controlled, dose-

escalation study in bunionectomy surgeries, which demonstrated

statistically significant reductions in average and worst pain scores

in the 1 mg Adlea dose group compared to placebo. In addition,

patients in the 1 mg Adlea group had a statistically significantly

longer median time to first use of an opioid or another acute pain

treatment compared to placebo. This Phase 2 trial is the basis for

the ongoing Phase 3 Adlea trial in bunionectomy surgeries, which

compares the same 1 mg Adlea dose to placebo control; the primary

endpoint in both trials is reduction in pain up to 32 hours post-

surgery for Adlea versus placebo.

* An exploratory clinical study in painful osteoarthritis of the knee

in which Adlea was generally well-tolerated, particularly when

stepwise dosing was used to reduce pain on injection in this non-

surgical setting. The study also generated longer-term data

suggesting reduced pain scores compared to baseline for up to the

eight week study endpoint.

* An independent presentation on long-term follow up from a study in

herniotomy surgeries which showed that, two years post-surgery, Adlea

treatment did not differ from placebo with regard to long-term

effects on sensory function in the surgical area.

* Preclinical studies suggesting that a single, clinically relevant

dose of Adlea does not have observable adverse effects on wound and

bone healing. A separate preclinical study demonstrated that a single

dose of Adlea caused a prolonged decrease in specific neuronal

markers and the TRPV1 receptor, suggestive of desensitization of the

nerve fibers, which gradually reversed
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 The “Molecular Diagnostic ... Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User ... Software) - Global Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure ... a worldwide leader in the development and sale ... life sciences research market, today announced that Professor ... a novel, accurate, highly reproducible, and robust method ... routine high-throughput protein analysis on small needle biopsy ...
(Date:10/26/2014)... (PRWEB) October 26, 2014 The report ... by Application - Global Trends & Forecast to 2019", ... analysis and forecasting of volume consumed and value generated. ... 4,253.9 KT in 2014 to 6,701.3 KT by 2019, ... , Browse 91 market data tables and 22 figures ...
(Date:10/25/2014)... According to new market research ... Types (Colocation, Enterprise, Telecom), by Design Types (Electrical, ... 2, Tier 3, Tier 4) - Global Forecast ... the Data Center Construction Market into various segments ... This research report also identifies the factors driving ...
Breaking Biology Technology:Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... (Nasdaq: PRXL ) will release Third Quarter Fiscal ... the close of the stock,market. The announcement will be ... the PR Newswire website at http://www.prnewswire.com ., ... webcast at 10:00 a.m. EDT,on Thursday, April 24, 2008 ...
... N.C., March 26 Campbell Alliance, the leading,management ... announced today that George Schmidt, Vice President,in the ... the EyeForPharma,Sales Force Effectiveness (SFE) conference. The event ... the Centre Convencions Internacional in Barcelona, Spain., ...
... March 26 /Xinhua-PRNewswire-FirstCall/,-- Kiwa Bio-Tech Products Group Corporation ... year ended December 31, 2007 were,$9,129,779 an increase ... sales from continuing operations were $9,129,779 and $2,506,715 ... 2006, respectively,representing an increase of $6,623,064 or 264.2%. ...
Cached Biology Technology:PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call 2Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference 2Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference 3Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 2Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 3Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 4Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 5Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 6Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 7
(Date:10/30/2014)... have developed a suite of technologies that can be ... has applications in everything from search and rescue to ... a platform for computer-mediated communication between humans and dogs ... dogs, behavioral signals and sending them clear and unambiguous ... professor of computer science at NC State and co-lead ...
(Date:10/30/2014)... 29, 2014  Securus Technologies, a leading ... solutions for public safety, investigation, corrections and ... exciting enhancements to its THREADS™ product, which ... actionable intelligence and focused leads for investigators. ... technological innovation through identifying and delivering solutions ...
(Date:10/29/2014)... lose their hair as a consequence of chemotherapy will ... the scalp cooling technology that prevents hair loss. , ... pioneered by global scalp cooling manufacturing company, Paxman Coolers, ... department of the University of Huddersfield. , The research ... has a background in the pharmacology of cancer treatment, ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... common form of brewer's yeast, University of Wisconsin-Madison researchers have ... to act as a master regulatory switch -- a control ... may contribute to serious neurological disorders. , The work, published ... shows how a mutation in a single gene can have ...
... to determine the sequence of nucleotide bases in the ... at UC San Diego and eight other universities and ... lower the cost to only $1,000 per human genome ... crucial to understanding and routinely treating hundreds of inherited ...
... have shown that some simple biodegradable liquids can stop ... could significantly impact medicine. , When the liquid, composed ... wounds, the peptides self-assemble into a nanoscale protective barrier ... the injury heals, the nontoxic gel is broken down ...
Cached Biology News:From a lowly yeast, researchers divine a clue to human disease 2Scientists win grants to develop $1,000 genome sequencing technology 2MIT material stops bleeding in seconds 2MIT material stops bleeding in seconds 3